 |
Montefiore-Einstein Center for Cancer Care
As the University Hospital for Albert Einstein College of Medicine, Montefiore believes very strongly in using the power of research to improve technologies, therapies and, ultimately, outcomes for our patients so they may live longer, healthier lives. Our partnership with Albert Einstein Cancer Center, a National Cancer Institute-designated Cancer Center, allows many of our oncologists, physicians and faculty members to participate in a wide array of clinical trials and other research studies.
We believe cancer treatments should be as unique as each of our patients. We are developing as many highly effective therapies as possible to offer patients ample options to determine the right drug—or combination of drugs—for their individual situation.
The Montefiore-Einstein Center for Cancer Care is engaged in a number of intriguing Phase I pharmacology clinical studies affecting a large number of cancers. Phase I studies allow us to examine how the body responds to the drug and investigate the side effects. We are also engaged in later phase studies in cooperation with our partners in industry, national oncology cooperative groups and the National Cancer Institute. New findings from the laboratories of our research partner, the Albert Einstein College of Medicine, are continuously evaluated for their potential for translation to our patients with cancer.
Our patients are given opportunities to participate in early-stage studies to determine if a new therapy effectively works for them. The trials are preceded by intensive and extensive laboratory research, and the potential benefits of participating in these clinical studies are numerous. They provide opportunities for our patients to receive the latest treatments long before they are available anywhere else.
At present, our Phase I studies include examining the use of Taxol®—already approved by the FDA for use in fighting breast and ovarian cancer—to tackle a number of different cancers. We are also evaluating a new agent, amrubicin, which is similar to adriamycin but with the potential for fewer side effects. In addition, we are developing novel ways to employ new and existing drug therapies, often in combination with other courses of treatment. Our program is also engaged in the study of tumor tissues to identify new targets for future therapies.
Trying an experimental therapy can be both exciting and a little frightening. Our focus is on the needs and concerns of participants, and we offer every assurance that each of our patients is completely in control of the process. We are vigilant about qualifying and approving candidates for specific studies. Additionally, each patient participates voluntarily and can choose to stop treatment at any time.
To inquire about clinical trials open to applicable participants, please call the Montefiore-Einstein Center for Cancer Care: 718-904-2730
Radiation Oncology Clinical Trials
Medial Epicondylitis (Golfer's or Baseball Elbow)
Pregnancy - Complications of Pregnancy
G6PD (Glucose-6-Phosphate Dehydrogenase) Deficiency
Care of the Uncircumcised Penis
